How to measure biomechanical properties today

Article

The primary function of biomechanical measurements is to improve safety and doctors can readily use these metrics in clinical practice today through the use of proxies, said William J. Dupps, MD.

The primary function of biomechanical measurements is to improve safety and doctors can readily use these metrics in clinical practice today through the use of proxies, said William J. Dupps, MD.

"Readily-measured variables that share some relationship to a biomechanical property of interest include central corneal thickness (CCT), corneal topography, or 'warpability', residual stromal thickness (RST) and time, which is useful to measure warpage recovery time," said Dr Dupps of the Cole Eye Institute, Cleveland, USA.

The advantage of proxies is that they can provide a rational, predictive variable for the safety of a given procedure, they are accessible and usually routine and population norms are well established.

He did, however, caution that there are problems using proxies. They are incomplete representations, they can be confounded by other uncontrollable or unmeasured variables and they can be insensitive to early disease.

Dr Dupps also reviewed the Ocular Response Analyser (ORA), which provides corneal hysteresis (CH) and corneal resistance factor (CRF) metrics, which provide keratoconic signals.

"While we are currently only using the corneal hysteresis value, clearly there is additional valuable information present in the shape of the measurement signal," he said.

Dr Dupps concluded by outlining tomorrow's challenges, among which are the need for a quantitative analysis of ORA signal morphology and to establish a conservative reference population as well as a "safe range" of CH, CRF and emergent variables.

Dr Dupps advised that the November issue of the Journal of Cataract and Refractive Surgery will report on advances in anatomic measurement.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.